Article Text

other Versions

Efficacy of mesalazine in IBS
  1. Thazin Min1,
  2. Alexander C Ford1,2
  1. 1Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK
  2. 2Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK
  1. Correspondence to Dr Alexander Ford, Leeds Gastroenterology Institute, Room 125, 4th Floor, Bexley Wing, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, UK; alexf12399{at}

Statistics from


We read the papers by Barbara et al1 and Lam et al2 with interest. The authors reported the results of two randomised controlled trials (RCTs) of mesalazine in IBS. These are the largest studies examining the efficacy of this drug in IBS, to date, and the authors are to be applauded for conducting them.

The efficacy of mesalazine in UC is undisputed.3–5 However, the observation that a subset of patients with IBS, particularly those with a post-infective aetiology, may demonstrate low-grade colonic mucosal inflammatory changes has led to a renewed interest in the use of the drug for this condition.6 …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.